Bulletin
Investor Alert

press release

Sept. 7, 2021, 4:06 p.m. EDT

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

REDWOOD CITY, Calif., Sep 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. /zigman2/quotes/216320743/composite RVMD -4.75% , a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23 [rd] Annual Global Investment Conference.

Details of the company's participation are as follows:

  • H.C. Wainwright 23 [rd] Annual Global Investment ConferenceConference Dates: September 13-15, 2021
    Presentation Timing: 7:00 a.m. Eastern on Monday, September 13, 2021
    Format: Virtual conference; webcast available

To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations . Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.







        Contacts:
        
        For Investors:
        Vida Strategic Partners
        Stephanie Diaz
        415-675-7401
        sdiaz@vidasp.com
        
        For Media:
        Vida Strategic Partners
        Tim Brons
        415-675-7402
        tbrons@vidasp.com
        


COMTEX_392933681/2471/2021-09-07T16:05:47

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/216320743/composite
US : U.S.: Nasdaq
$ 23.05
-1.15 -4.75%
Volume: 1.33M
Aug. 18, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.08 billion
Rev. per Employee
$144,973
loading...

Partner Center

Link to MarketWatch's Slice.